Kornimate/medical-research-clean huggingface dataset:
study evaluating near-infrared imaging coupled with indocyanine green for intraoperative control of resection margins in ent surgery

Conditions: Head and Neck Cancer

Summary: assess the sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after a complete macroscopic surgical resection of head and neck cancers


Eligibility criteria:
inclusion criteria: * male or female 18 years of age or older * ecog performance status 0-2 * histological confirmation of squamous cell carcinoma * locating the primary tumour in the oral cavity or oropharynx * disease operable for complete resection * serum or urinary pregnancy test (as per centre practices) negative within 14 days prior to systemic indocyanin green injection (pre-operative visit), for women of childbearing age * patient information and signed free and informed consent * patient affiliated with a social security scheme or beneficiary of a similar scheme. * the patient must understand, sign and date the consent form prior to any protocol-specific procedures. the patient must be able and willing to comply with the study visits and procedures described in the protocol exclusion criteria: * severe medical co-morbidities or contraindications to surgery * primary tumour not operable * history of head and neck cancer in the past 5 years * history of radiation for head and neck cancer * metastatic cancer * tumours with necrosis ranges in pre-operative imaging * history of invasive cancer unless there has been no recurrence for more than 5 years with an exception for non-melanoma skin cancers. * pregnant or nursing woman * allergy or hypersensitivity to the product being administered (its active substance or other ingredients), iodized products or crustaceans. * hyperthyroidism, thyroid adenoma, unifocal, multifocal or multinodular goiter of autoimmune origin. * documented coronary artery disease * advanced renal failure (creatinine \> 1.5mg/dl). * within 2 weeks prior to inclusion, concomitant medication that reduces or increases extinction of gi (i.e. anticonvulsants, haloperidol and heparin). * patient under guardianship or curatorship or deprived of liberty by judicial or administrative decision or patient unable to give consent. * patients unable to undergo medical follow-up of the trial
the effect of smartphone addiction and mental fatigue on working memory in university students

Conditions: Smartphone Addiction; Mental Fatigue

Summary: the aim of this study is to investigate the effects of smartphone addiction and mental fatigue on working memory in university students.

university students who meet the inclusion and exclusion criteria will be informed about the study and the participants who agree to participate in the study will be given the turkish version of "smartphone addiction scale", ''mental fatigue scale'' and "working memory questionnaire" tests, respectively. 120 university students will included in the study. to evaluate between correlation of tests will used to correlation analysis tests. in addition, it will be investigated whether there is a difference between 1.2.3 and 4th grades in terms of smartphone addiction, mental fatigue scale and working memory questionnaire

Eligibility criteria:
inclusion criteria: * being a university student * be between the ages of 18-25 * using a smartphone for at least one hour a day exclusion criteria: * having musculoskeletal pain * having had surgery in the last 6 months * decline to participate in the study

Keywords: working memory mental fatigue smartphone addiction
treatment of asymptomatic bacteriuria in pregnancy

Conditions: Bacteriuria (Asymptomatic) in Pregnancy

Summary: this is a prospective randomized controlled day comparing the efficacy of three-day antimicrobial treatment of asymptomatic bacteriuria (asb) in pregnancy to the standard seven-day treatment. half the patients will receive 3-day treatment and the other half will receive 7 days of antibiotics.

the current standard of practice is to treat pregnant patients with asb with a 7-day course of oral antimicrobial agents. if bacteriuria persists women are retreated with the same of different agent for a second course of 7 to 14 days and they may be subsequently placed on prophylaxis. in nonpregnant women, an uncomplicated lower urinary tract infection may be treated with a short course regimen from 1 to 3 days. this approach has similar rates of persistent bacteriuria or symptoms following treatment when compared to women treated with a more conventional approach. if the infection recurs or persists, the patient may then be treated with the more traditional 7 to 14 day course. the advantages of single-dose regimens are cost and patient compliance, but a major disadvantage is the failure to eradicate uropathogens from the vaginal reservoir, which results in more frequent early recurrences. the three-day regimen is advocated to maintain the advantages of lower costs and patient compliance but improving cure rates. multiple studies have shown the advantage of even a short course of antibiotics as opposed to no treatment.

Eligibility criteria:
inclusion criteria: * pregnant women ≥ 18 years of age seeking prenatal care at the academic obstetrics and gynecology center at st. joseph mercy hospital, ann arbor, michigan * randomization will occur if the patient every has a urine culture demonstrating ≥10,000 cfu/ml of a pathogenic urinary tract organism exclusion criteria: * symptomatic bacteriuria (cystitis or pyelonephritis) at the time of urine collection * previously treated bacteriuria in current pregnancy * past medical history of known congenital or acquired urinary tract anomaly or abnormality (i.e. pelvic kidney, single kidney, renal transplant) * any antibiotic use within the week prior to urine sampling * urine culture revealing growth of the following organisms: lactobacillus, coagulase-negative staphylococcus
evaluate the effectiveness and safety of raman ivd analyzer in the molecular diagnosis of gliomas during surgery

Conditions: Glioma

Summary: to distinguish various molecular subtypes of gliomas by spectra data obtained from raman analyzer, including idh mutant, 1p/19q-codeleted, atrx deletion, tert promoter mutation, mgmt promoter methylation, egfr amplification, h3 k27-altered, tp53 mutant, pten deficiency, ki 67, aqp4, vegf, and so on, comparing with the results of immunohistochemistry or genetic test on the same brain tissue samples.

1500 samples were included retrospectively with the spectra data obtained from raman analyzer to establish clinical intelligence model, modifying the analyzer. based on statistical calculations, 200 glioma samples will be included in the trial in all trial centers prospectively. compare the results between the raman analyzer and immunohistochemistry or genetic test results. and calculate the auc, the accuracy, sensitivity, the specificity, and other indicators of raman analyzer. during surgery, core tissue samples were taken from subjects. the test samples size:0.2cm\<length diameter ≤ 2cm. the sample testing result is based on the raman test points. then take the same tissue sample for immunohistochemistry or genetic test. statistical description of all data, including baseline data, all efficacy indicators, and all safety data. the measurement data give the mean, standard deviation, minimum, maximum, median,25 quantile and 75 quantile; provide frequency and composition ratio for counting data. the baseline data was analyzed using the full analysis set (fas); the effectiveness analysis adopts fas and pps; the security analysis uses the security dataset (ss).

Eligibility criteria:
inclusion criteria: * patients who plan to undergo brain lesion tissue resection surgery or have preoperative clinical diagnosis of gliomas and plan to undergo biopsy; * patients with clinical diagnosis of initial solitary gliomas, or initial solitary intracranial masses or initial non occupying lesions that do not exclude gliomas (such as intracranial metastatic lesions, intracranial infectious lesions, intracranial demyelinating lesions, central nervous system lymphoma, etc.), who have not received radiotherapy or chemotherapy in the past based on their medical history; * the patient or their guardian can understand the research purpose, demonstrate sufficient compliance with the trial protocol, consent for immunohistochemistry or genetic test, and sign an informed consent form; * it is possible to obtain tissue samples with a length diameter greater than 0.2cm. patients diagnosed with initial solitary glioma should take core or marginal tissue, while patients diagnosed with initial single intracranial mass or initial non mass lesions but maybe with gliomas should be taken core tissue. exclusion criteria: investigator judge that it is not suitable for inclusion.

Keywords: molecular subtype raman intraoperative surgery
gap co2 in septic patient to predict cardiomyopathy septic

Conditions: Gap co2; Cardiac Output, Low; Cardiac Defect

Summary: the investigators included 98 patients admitted for sepsis and septic shock (68.4% men, 31.6% women) with an average age of 60.42 years ± 15.13, ranging from 21 to 96 years. the average length of hospital stay was 7.53 days. the most noted medical histories were diabetes (38.8%), hypertension (28.6%), and renal insufficiency (17.1%). regarding laboratory findings: the mean white blood cell count was 15,985.16 cells/mm³, the mean c-reactive protein (crp) level was 227.69 mg/l, and the mean procalcitonin level was 50.43 µg/l. in terms of blood gas analysis: the mean lactate level was 3.67 mmol/l, and the mean pco2 gap (deltapco2) was 4.85. all our patients were continuously monitored by pulse wave analysis: the mean cardiac output was 5.69 l/min, and the mean cardiac index was 4.14 l/s/m² all our patients underwent an echocardiogram, which is a routine examination in our department and is performed at the patient's bedside. the average left ventricular ejection fraction (lvef) was 51.73%, and the average subaortic peak velocity (itv) was 14.66 cm. subsequently. the investigators examined the clinical and paraclinical profile of patients with septic cardiomyopathy. the investigators identified 19 patients with this condition, while 79 patients did not exhibit cardiac involvement. the percentage was significantly higher in the population with cardiac involvement, accounting for 28.3%. among the patients with cardiac involvement, 76.5% had a pco2 gap (deltapco2) ≥ 6 mmhg, a significantly reduced cardiac output with an average of 3.3 l/min, and a predominantly low cardiac index, with 64.3% having an index \< 2.2 l/min/m². the mortality rate was significantly increased at 73.7%.


Eligibility criteria:
inclusion criteria: * patients admitted to the intensive care unit * sepsis or septic shock * at least one echocardiogram and were monitored by pulse wave contour analysis * stay of 72 hours in the intensive care unit exclusion criteria: * patients without sepsis or septic shock. * patients with covid-19. * patients who died within 48 hours of hospitalization. * cases with incomplete medical records or patients not monitored. * patient with pre-existing cardiac conditions. * post-operative patients from cardiac and thoracic surgeries.

Keywords: cardiac co2 septic
mobile application for relapse prevention in eating disorders beliefs in three patients in remission.

Conditions: Eating Disorders

Summary: this study aims to assess the efficacy of gged module in preventing relapse in three patients with ed diagnoses in remission. in particular, the objective of the present study is to analyse whether the gged module diminishes the level of attachment to dysfunctional beliefs related to the maintenance of eds, which had previously been addressed in cbt therapy. specifically, an uncontrolled case series design was carried out to assess the changes pre and post use the app. it's expected that after the use of the gged module for 15 days are, the patients show at the primary level: decrease in the degree of ascription to dysfunctional beliefs associated with ed; and at the secondary level: increase in self-esteem and body satisfaction; decrease in eating symptomatology; and no changes in emotional symptomatology. these results are also expected to be maintained in subsequent follow-ups, at 15 days and a month after to finish the app.

there is a mobile platform, called ocd.app (previously ggtude) which is an evidence-based platform comprising of brief game-like exercises targeting a wide range of psychological symptoms. gged (gg eating disorders) is a module within the app that addresses the core beliefs related to the development and maintenance of eating disorders. in this, a cognitive training exercise is performed: different sentences appear in the form of beliefs, and the person must identify and accept those beliefs that are functional, adaptive and positive, dragging them to the lower part of the screen; and reject those that are dysfunctional, maladaptive and negative dragging them to the upper part of the screen. gged has shown promising results in reducing maladaptive beliefs in the general adult population and in general adolescent population. in addition, another module that target on obsessive-compulsive disorder (ocd) has demonstrated its efficacy in preventing relapses in patients diagnosed with ocd in remission. given that the gged module has not yet been tested in eds patients and there is a need for the development of techniques to prevent relapses in these disorders, the objective of the present study is to assess its efficacy in preventing relapse in three patients with ed diagnoses in remission.

Eligibility criteria:
inclusion criteria: * (1) informed consent signed; (2) a diagnosis of an ed in remission; (3) having received cbt; (4) and access to a mobile device to complete the gged module. exclusion criteria: * (1) not meeting the described inclusion criteria.

Keywords: maladaptive beliefs relapse prevention mobile app patients case series study
national stigma survey about mental illness, intellectual disability and homelessness in spain

Conditions: General Population

Summary: this project is framed within the "complutense university of madrid (ucm)-group 5 against stigma chair", of the faculty of psychology. the main objective of the chair is to fight the stigma that affects people with mental disorders, disabilities, vulnerability or extreme social exclusion. for this purpose, the chair is developing research studies, training programs, cultural activities and awareness campaigns, proof of this is the recent publication of the guide to good practices against stigma, which, although it takes as a reference to the people with a diagnosis of mental disorder, it is expected to be generalizable to other groups. stigma is associated with the condition of being different, and affects any person belonging to a minority or vulnerable group, being one of the main obstacles to full participation in different social, political and cultural institutions. the fight against stigma is included in important international treaties, such as the united nations convention on the rights of persons with disabilities or the european recommendations regarding the fight against social exclusion of people with mental health problems. this study will focus on three groups of special social sensitivity, with clear stigmatizing conditions: people with mental health problems, people in a homeless situation and people with intellectual disabilities.

the primary aim of this research is to describe the stigma faced by people corresponding to three highly vulnerable population groups: people with mental health problems, homeless people and people with intellectual disabilities. from this general aim, four different specific goals are derived: 1) to delve into the experience of stigma of these groups, from first person; 2) to develop a quantitative assessment instrument that captures the current needs and experiences of people from these groups; 3) to describe and compare the social stigma of these three groups in a representative spanish sample; 4) to address, from a gender perspective, possible differences in terms of the variables explored in the populations under study.

Eligibility criteria:
inclusion criteria: * people aged 18 and over from general population. * any gender. exclusion criteria: * people under 18 years old.

Keywords: stigma mental illness homeless situation intellectual disability
intervention study on life review among advanced cancer patients in fuzhou, china

Conditions: Advanced Cancer

Summary: this study aims to develop a life review program and test its effectiveness on a sample of patients with advanced cancer patients receiving palliative care at home in fuzhou.

a life review program is mainly developed based on erickson's theory, confucius's teaching on human development, and the empirical findings of the researcher's preliminary study and pre-pilot study. the program covers reviewing a life for advanced cancer patients and formulating a booklet for them. a randomized controlled trial will be adopted for evaluation of this program. eligible patients will be randomly assigned to the experimental group and the control group. the subjects in the experimental group will receive a life review program for three weeks. the outcome measure is quality of life (qol), including domains of physical discomfort, food-related concerns, health care concerns, support, negative emotions, sense of alienation, existential distress and value of life. subjects' qol will be assessed before commencement of the program (t0) and one day (t1) and three weeks (t2) after the completion of the program for all subjects in two groups. perceptions of the program will be elicited within three days after the program for subjects in the experimental group.descriptive statistics will be used to analyze patients' personal information, disease related information, functional performance and qol of advanced cancer patients. repeated measures anova will be used to measure qol differences in between-group, within-group and interaction effects. content analysis will be used to analyze the qualitative data collected.

Eligibility criteria:
inclusion criteria: 1. patients who are newly admitted to the study hospice 2. patients who are suffering from cancer with metastasis made by a physician 3. patients who know their diagnosis, prognosis and therapy 4. patients' functional performance (the score of kps) at or more than 50% 5. patients who are adults (≥18 years old) 6. patients who have no cognitive and verbal communication impairments exclusion criteria: 1. patients with planned treatments, such as chemotherapy, radiotherapy or surgery 2. patients with psychiatric disorders 3. patients who live outside fuzhou since the following-up home visit services are not extended to those areas

Keywords: life review quality of life advanced cancer patients
circulating biomarkers and ventricular tachyarrhythmia

Conditions: Cardiomyopathy; Ventricular Tachycardia; Ventricular Fibrillation

Summary: the purpose of this study is to determine whether levels of inflammatory markers in circulating blood can correlate with risk for dangerous heart rhythms. patients with systolic heart failure, which has been shown to increase risk for dangerous heart rhythms, will be enrolled. all subjects will have an implantable cardioverter-defibrillator (icd) in place, which allows regular evaluation of heart rhythm.

if you agree to be in this study, you will be asked to the following things: * you will come into the ep device clinic every three months for one year to have your device interrogated and will complete an ekg * you will have labs drawn to measure levels of certain markers of inflammation in the body. this information will be used to identify new ways to test for risk of abnormal heart rhythms and other heart disease * you will review your medications with the study coordinator and along with any recent illnesses or hospitalizations

Eligibility criteria:
inclusion criteria: * left ventricular ejection fraction \[lvef\] \<=35% * icd implant exclusion criteria: * recent myocardial infarction (12 weeks) * recent revascularization (12 weeks) * recent hospitalization for any cause (6 weeks) * history of rheumatologic disease
a first-in-human study of cee321 in adult subjects

Conditions: Atopic Dermatitis

Summary: open label, non-randomized, uncontrolled, first-in-human phase 1 study in healthy subjects and subjects with atopic dermatitis


Eligibility criteria:
key inclusion criteria for healthy subjects (part a) * written informed consent * able to communicate well with the investigator to understand and comply with the requirements of the study, including skin biopsies * healthy male and female subjects aged ≥18 and ≤ 65 years * able to comply with requirement of domiciliation at the investigational site key exclusion criteria for healthy subjects (part a) * subjects with a history of hypertrophic scars or keloids. * any infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals and/or hospitalization, isolation, quarantine within 4 weeks prior to first treatment * women of childbearing potential defined as all women physiologically capable of becoming pregnant. * history of drug or alcohol abuse within the 12 months prior to dosing key inclusion criteria for atopic dermatitis subjects (part b) * written informed consent * able to communicate well with the investigator to understand and comply with the requirements of the study, including skin biopsies * adult male or female subjects aged ≥18 and ≤ 65 years with confirmed clinical diagnosis of atopic dermatitis (ad) key exclusion criteria atopic dermatitis subjects (part b) * subjects with a history of hypertrophic scars or keloids. * any infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals and/or hospitalization, isolation, quarantine within 4 weeks prior to first treatment * women of childbearing potential defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception * history of drug or alcohol abuse within the 3 months prior to dosing * any skin disease that, in the opinion of the investigator, would confound the diagnosis or evaluation of ad disease activity * clinical significant medical condition, including psychiatric condition, which in the investigator's opinion may interfere with safety of subjects, study objectives or adherence to the protocol.

Keywords: first-in-human healthy volunteers atopic dermatitis cee321 safety tolerability pharmacokinetics
evaluation of dental caries using caries assessment spectrum and treatment need (cast) index, international caries detection and assessment system (icdas) index and world health organization (who) index

Conditions: Caries Experience

Summary: this study goals is to compare the three indices in egyptian children aged 4 to 6 years in caries detection and time needed for the assessments which will contribute to valuable data for pediatric oral health assessments both locally and globally.

this study will ensure that patients receive precise evaluations and guide early, appropriate preventive measures or treatments. over time, this will contribute to reducing caries progression and related complications. also, parents become more aware of their children's dental health status, emphasizing the importance of early detection and intervention.furthermore , comparing the indices will provide insights into which tool is most efficient and reliable for detecting caries in preschool children.

Eligibility criteria:
inclusion criteria: * children aged 4-6 years. * written consent from parents or guardians for participation. * children who are cooperative during clinical examinations. exclusion criteria: * children with systemic and mental diseases that might affect dental health. * teeth with developmental anomalies that interfere with caries assessment. * teeth with extensive restorations.